Emergent Non Currrent Assets Other from 2010 to 2025
EBS Stock | USD 4.66 0.26 5.28% |
Non Currrent Assets Other | First Reported 2004-12-31 | Previous Quarter 20.5 M | Current Value 18.9 M | Quarterly Volatility 54.6 M |
Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent Biosolutions' main balance sheet or income statement drivers, such as Depreciation And Amortization of 114.2 M, Interest Expense of 74.5 M or Total Revenue of 583.9 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.018 or PTB Ratio of 1.0. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules.
Emergent | Non Currrent Assets Other |
Latest Emergent Biosolutions' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Emergent Biosolutions over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Emergent Biosolutions' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emergent Biosolutions' overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
Timeline |
Emergent Non Currrent Assets Other Regression Statistics
Arithmetic Mean | 51,339,688 | |
Geometric Mean | 18,792,377 | |
Coefficient Of Variation | 125.49 | |
Mean Deviation | 52,795,234 | |
Median | 17,955,000 | |
Standard Deviation | 64,423,814 | |
Sample Variance | 4150.4T | |
Range | 190.6M | |
R-Value | 0.37 | |
Mean Square Error | 3840T | |
R-Squared | 0.14 | |
Significance | 0.16 | |
Slope | 4,998,816 | |
Total Sum of Squares | 62256.4T |
Emergent Non Currrent Assets Other History
About Emergent Biosolutions Financial Statements
Emergent Biosolutions shareholders use historical fundamental indicators, such as Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may analyze each financial statement separately, they are all interrelated. The changes in Emergent Biosolutions' assets and liabilities, for example, are also reflected in the revenues and expenses on on Emergent Biosolutions' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Non Currrent Assets Other | 18.9 M | 18 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.